Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
CytoDyn Inc.
- Market Cap
- Unavailable
- Price
- $0.21
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.94%
- Volume
- 803.7K
About
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
Quick stats
Shares outstanding—
Computed float1.4B
Float / sharesUnknown
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001175680
Websitehttps://www.cytodyn.com
AI Summary
AI-generated1/17
standardbullishclinical trial
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
CytoDyn announced the first patient has been dosed in the SALIENT-AD Phase 2a study, a collaboration with Weill Cornell Medicine evaluating leronlimab in Alzheimer’s disease.
The open-label proof-of-concept study will enroll 10 to 20 patients over age 50 with early-stage, biomarker-confirmed Alzheimer’s, receiving weekly subcutaneous injections for 12 weeks.
The primary endpoint assesses changes in brain inflammation and microglial activation using PET imaging, while secondary endpoints include safety, cognitive assessments, and blood-based biomarkers.
CEO Jacob Lalezari noted that while oncology remains the primary focus, this study explores a significant unmet need in neuroinflammation, leveraging leronlimab’s CCR5-targeting mechanism.